Immune–tumor cell ligand–receptor axes driving metabolic reprogramming and therapeutic resistance in cancer
Therapeutic resistance remains a major barrier to durable cancer control and cannot be fully explained by tumor-intrinsic genetic and epigenetic alterations alone. Increasing evidence indicates that resistance emerges within a dynamic tumor microenviro…